VitalHub Corp. (VHI.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

VitalHub Corp. (VHI.TO)

8.04

-0.19 (2.31%)

as of Sep 4, 2026, 8:00:00 pm Market Open.

106 watching

Investor Insights

Sep 6, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

VitalHub Corp. (VHI-T) has established itself as a leader in providing technology solutions for healthcare in Canada and the UK. Despite facing a selloff due to its recent mergers and acquisitions, analysts remain optimistic about the company's mission-critical services that are vital in hospitals and ultimately save lives. The most recent quarterly report revealed better-than-expected revenues of $32 million, with a strong annual recurring revenue (ARR) of $93.7 million, benefiting from both organic growth and acquisitions. Analysts suggest that while the integration of the new acquisitions may take time, the company is on the right track and leveraging operational efficiencies through global strategies such as outsourcing work to Sri Lanka. Overall, observers see VHI as a high-quality, long-term investment opportunity worth holding onto amidst a challenging competitive landscape, particularly against larger companies like Oracle.

Consensus

Positive

Valuation

Undervalued

Similar

Cerner,CERN

TOP PICK

Margins are 22% and the company projects 40%. Trades at 18-19x PE. Will grow topline at 15-20% annually for the next 5 years as profits grow faster. Is the next Descartes.

(Analysts’ price target is $6.45)

BUY

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

2Q sales rose 38% to $13.1M; margins dipped to 81% from 83% due to an increase in lower margin service revenue. EBITDA nearly doubled to $1.9M. Net income was $0.72M from a loss last year. Cash was $22M. Results look good to us; Cormark raised its target price slightly. EPS is predicted to double in 2024, with slower growth following the next year.
Unlock Premium - Try 5i Free

BUY ON WEAKNESS

Healthcare tech company.
Has owned on and off over the past few years.
Very strong management team.
Multiple is high given current share price.
Defensive software name.

Unspecified

It is a patient flow technology company combining health and technology. He has held it off and on in varying amounts over the years. Management has done a great job growing the business and producing recurring revenue. Although it is doing the right things he would like to see more profitability and a higher ROE.

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales growth has restarted. Margins contracted slightly. Revenues increased by 36% from the same quarter a year prior. They overall missed their quarter but growth prospects still look pretty good. Unlock Premium - Try 5i Free

PARTIAL BUY

He got in very early at 15 cents. Their software help hospitals manage patients and increase efficiency. Very active in the UK. Management has built a company like this before and are doing it again now. Topline growth has been great, but he'd like to see more profit growth. The stock is a good trader around $3 where it has been stuck. This could be a take-out candidate one day, but nothing is imminent.

PARTIAL BUY

They are buying small healthcare tech companies. They have been executing the acquisition plan at a pretty good pace. Sometimes it gets lumped in with the more speculative healthcare tech companies. They have a lot of cash on the balance sheet. (Analysts’ price target is $4.77)

RISKY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Competition in the space has increased. The valuation has reached above 6x sales. Valuation is more reasonable at 3x sales. The company also has small cap risk but sales growth has been strong. A 5+ years time horizon. Unlock Premium - Try 5i Free

WATCH

He kind of likes this business. The valuation is more reasonable than some others in the space. He is keeping his eye on it. They are in a good segment of the business.

COMMENT

He spoke with management about 2 weeks ago. 2020 is the year of great opportunity for them. They continue to win large contracts here and in the Middle East. He does not own it. (Analysts’ price target is $3.25)

COMMENT

Something happened to this on Jan. 6 (a 10-2 stock split), and it's up 1,100% this month. Hard to talk about this, technically. Do fundamental analysis. Maybe enter at $2.20. Reverse consolidations are usually not good.

WATCH

Tech analysis on penny stocks is very difficult. We need to get through somewhere we haven't been. Have to prove the stock wants to go higher.

DON'T BUY

It's starting to look toppy. He needs it to rise above its current price range before he'd buy.

BUY

It's tried many times to rise above 20 cents, beyond a spike, and he'd love it to do that. He would gamble on that happening. It's long been steady.

Showing 16 to 29 of 29 entries

Most Recent Experts

Kevin Simpson

Capital Wealth Planning

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brian Madden

First Avenue Investment Counsel

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

VitalHub Corp. (VHI.TO)